title: Plasma osteopontin velocity differentiates lung cancers from controls in a CT screening population.
abstract: BACKGROUND
  As CT screening is integrated into non-small cell lung cancer (NSCLC) care, additional parameters are needed to help distinguish cancers from benign nodules. Osteopontin (OPN), a secreted phosphoprotein, has elevated plasma levels in NSCLC. We hypothesize that changes in plasma OPN over time (i.e., OPN velocity [OPNV]) can differentiate NSCLC patients from those without cancer in a CT screening population.
  
  
  METHODS
  A nested case-control study was conducted within a NSCLC CT screening trial. Incident cancers with serial plasma were matched to controls. OPN was measured by ELISA. Demographic, OPN, and OPNV were compared between cancers and controls using Wilcoxon Signed Rank tests.
  
  
  RESULTS
  Ten incident cancers were identified. The pack years distributions were similar, but cancers were older (median of the paired difference: 5.35 years; p=0.002) and their surveillance intervals were shorter (median of the paired difference: -2 months; p=0. 03) than matched controls. Baseline OPN was similar (median of the paired difference: -5.15 ng/ml, p=0.50), but OPNV in the cancers was significantly greater than that of matched controls, (median of the paired difference: 1.06 ng/ml/month, p=0.01). Accuracy rate for prediction of disease status based on OPNV (adjusted for age and surveillance) was 83%.
  
  
  CONCLUSIONS
  These are early evidence for utility of monitoring plasma OPN during CT screening to assist in identification of NSCLCs.
authors.affiliation: Thoracic Oncology Laboratory, Department of Cardiothoracic Surgery, NYU School of Medicine, New York, NY 10016, USA.
authors.forename: Sasha
authors.initials: S
authors.lastname: Joseph
authors.forename: Ryan
authors.initials: R
authors.lastname: Harrington
authors.forename: Dawn
authors.initials: D
authors.lastname: Walter
authors.forename: Judith D
authors.initials: JD
authors.lastname: Goldberg
authors.forename: Xiaochun
authors.initials: X
authors.lastname: Li
authors.forename: Amanda
authors.initials: A
authors.lastname: Beck
authors.forename: Tyler
authors.initials: T
authors.lastname: Litton
authors.forename: Nathalie
authors.initials: N
authors.lastname: Hirsch
authors.forename: Justin
authors.initials: J
authors.lastname: Blasberg
authors.forename: Mark
authors.initials: M
authors.lastname: Slomiany
authors.forename: William
authors.initials: W
authors.lastname: Rom
authors.forename: Harvey
authors.initials: H
authors.lastname: Pass
authors.forename: Jessica
authors.initials: J
authors.lastname: Donington
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D019540:Area Under Curve; D014408:Biomarkers, Tumor / Q000097:blood*; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000000981:diagnostic imaging*; D016022:Case-Control Studies; D003937:Diagnosis, Differential; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood / Q000000981:diagnostic imaging*; D008875:Middle Aged; D053495:Osteopontin / Q000097:blood*; D012372:ROC Curve; D014057:Tomography, X-Ray Computed
chemical_list: D014408:Biomarkers, Tumor; D053495:Osteopontin